SetPoint Medical
27441 Tourney Road
Suite 200
Valencia
California
91355
United States
Tel: 661-750-2661
Website: http://www.setpointmedical.com/
38 articles about SetPoint Medical
-
SetPoint Medical Accepted into FDA Total Product Life Cycle Advisory Program for Development of its Neuroimmune Modulation Platform for the Treatment of Multiple Sclerosis
3/21/2024
SetPoint Medical, a clinical-stage healthcare company dedicated to patients with chronic autoimmune diseases, announced that it has been accepted into the Total Product Life Cycle Advisory Program Pilot from the U.S. Food and Drug Administration for the development of its novel neuroimmune modulation platform for people living with relapsing-remitting multiple sclerosis.
-
SetPoint Medical Receives FDA Breakthrough Device Designation for its Neuroimmune Modulation Platform for the Treatment of Multiple Sclerosis
3/13/2024
SetPoint Medical Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the use of its novel neuroimmune modulation platform for people living with relapsing-remitting multiple sclerosis (RRMS).
-
SetPoint Medical Announces Publication of Data for Neuroimmune Modulation to Treat Crohn's Disease in Journal of Crohn's and Colitis
10/3/2023
SetPoint Medical, a clinical-stage healthcare company dedicated to patients with chronic autoimmune diseases, today announced the publication of data from a multicenter European clinical trial evaluating the safety and efficacy of neuroimmune modulation in patients with treatment-refractory Crohn’s disease in the Journal of Crohn’s and Colitis.
-
SetPoint Medical Appoints Rohan Seth as Chief Financial Officer
6/12/2023
SetPoint Medical, a clinical-stage healthcare company dedicated to patients with chronic autoimmune diseases, announced the appointment of Rohan Seth as Chief Financial Officer.
-
SetPoint Medical Announces Expanded $65M Credit Facility to Support Development of the Company’s Novel Platform for Rheumatoid Arthritis
1/19/2023
SetPoint Medical today announced a senior secured term loan facility of up to $65 million from Runway Growth Capital LLC (“Runway”), a leading provider of growth loans to both venture and non-venture backed companies.
-
SetPoint Medical Announces $80M Preferred Stock Financing to Advance Company’s Novel Treatment for Autoimmune Diseases
1/19/2023
SetPoint Medical, a clinical-stage healthcare company dedicated to patients with chronic autoimmune diseases, today announced an $80 million preferred stock financing co-led by new investors Norwest Venture Partners and Viking Global Investors.
-
First Patient Enrolled in Stage 2 of Pivotal Study of SetPoint Medical’s Pioneering Technology for the Treatment of Rheumatoid Arthritis
10/10/2022
SetPoint Medical , a clinical-stage healthcare company dedicated to patients with chronic autoimmune diseases, announced the enrollment of the first participant in Stage 2 of the company's RESET-RA pivotal study.
-
The FDA has a broad range of activities in the drug and medical device space. Here’s a look at the agency’s work this week.
-
SetPoint Medical Announces FDA Approval for Continuation of the RESET-RA Pivotal Study
9/13/2022
SetPoint Medical , a clinical-stage healthcare company dedicated to patients with chronic autoimmune disease, announced U.S. Food and Drug Administration (FDA) approval for continuation of the company’s RESET-RA study.
-
SetPoint Medical CEO Murthy Simhambhatla Named to AIMBE College of Fellows
3/3/2021
SetPoint Medical, a clinical-stage bioelectronic medicine company developing therapy for chronic autoimmune diseases, announced that the American Institute for Biological and Medical Engineering has elected Murthy Simhambhatla, PhD, to the AIMBE College of Fellows for “outstanding contributions as a medical technology innovator and business leader, advancing health for millions of patients around the world.”
-
SetPoint Medical Announces First Patient Enrolled in the RESET-RA StudyPivotal IDE Study will evalute SetPoint’s propriertary bioelectronic device for treatment of Rheumatoid Arthritis
2/1/2021
SetPoint Medical, a clinical-stage bioelectronic medicine company developing therapy for chronic autoimmune diseases, today announced the enrollment of the first patient in the company’s RESET-RA study.
-
SetPoint Medical Raises $64M in Preferred Stock Financing to Support Pivotal Trial for its Novel Bioelectronic Platform
1/27/2021
SetPoint Medical Corporation today announced raising $64M in a Preferred Stock Financing to support its RESET-RA pivotal trial in patients with rheumatoid arthritis (RA).
-
Many drug makers are investing in new science and hope to develop new therapeutics that address autoimmune disease. BioSpace has captured some key efforts.
-
SetPoint Medical Receives FDA Breakthrough Device Designation for its Novel Bioelectronic Platform
10/6/2020
SetPoint Medical, Inc. today announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the use of its novel bioelectronic device for patients with rheumatoid arthritis (RA) who have incomplete response to, or are intolerant to multiple biologic drugs
-
The Lancet Rheumatology Publishes Clinical Trial Data Demonstrating Promising Safety and Efficacy Profile for a Novel Bioelectronic Device in Patients with Drug Refractory Rheumatoid Arthritis
7/29/2020
Device reduced disease activity in 50% of patients who had failed multiple drug classes including Janus Kinase Inhibitors (JAKi)
-
SetPoint Medical Receives IDE Approval for U.S. Pivotal Trial to Study its Bioelectronic Platform in Rheumatoid Arthritis Patients
5/6/2020
SetPoint Medical, a clinical-stage bioelectronic medicine company developing therapy for chronic autoimmune diseases, today announced that it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to study its proprietary bioelectronic platform in patients with rheumatoid arthritis (RA).
-
SetPoint Medical to Present at Canaccord Genuity Medical Technologies & Diagnostics Forum 2019
11/14/2019
SetPoint Medical, a clinical-stage bioelectronic medicine company developing therapy for chronic autoimmune diseases, today announced that Murthy Simhambhatla, Ph.D., President and Chief Executive Officer, is scheduled to present at the 13th annual Canaccord Genuity Medical Technologies & Diagnostics Forum, being held November 21, 2019 in New York, New York.
-
SetPoint Medical Announces Oral Presentation of Results from U.S. Pilot Study in Rheumatoid Arthritis Patients at American College of Rheumatology (ACR) Annual Meeting 2019
10/29/2019
SetPoint Medical, a clinical-stage bioelectronic medicine company developing therapy for chronic autoimmune diseases, today announced that results from its U.S. pilot Investigational Device Exemption (IDE) study in rheumatoid arthritis (RA) have been accepted for oral presentation at the American College of Rheumatology (ACR) Annual Meeting, being held November 8-13, 2019 in Atlanta, GA
-
SetPoint Medical Reports New Data Demonstrating its Bioelectronic Medicine Effectively Reduces Crohn’s Disease Activity
5/20/2019
Results Delivered in Oral Presentation at Digestive Disease Week 2019
-
SetPoint Medical Completes Enrollment in U.S. Pilot Study Evaluating Bioelectronic Device for Treatment of Rheumatoid Arthritis
10/18/2018
Proprietary Device Delivers Doses of Electricity to Activate Systemic Anti-inflammatory Response